Intracellular antibodies and cancer: New technologies offer therapeutic opportunities

BioEssays

Volumn 32, Issue 7, 2010, Pages 589-598

  Pérez Martínez, David ^a   Tanaka, Tomoyuki ^a   Rabbitts, Terence H ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Antibody fragment; IAC; iDab; scFv; Therapy

Indexed keywords

CELL ANTIBODY;

APOPTOSIS; BINDING SITE; DRUG BINDING; HUMAN; IN VIVO STUDY; LIBRARY; MOLECULE; NEOPLASM; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SCREENING; TARGET CELL; TECHNOLOGY; VIRAL GENE DELIVERY SYSTEM;

ANTIBODIES; DRUG EVALUATION, PRECLINICAL; HUMANS; INTRACELLULAR SPACE; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN ENGINEERING;

EID: 77954840147     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201000009     Document Type: Review

References (95)

1. Blundell TL, Sibanda BL, Montalvao RW, et al. 2006. Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Philos Trans R Soc Lond B Biol Sci 361: 413-23.
2. Wells JA, McClendon CL. 2007. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001-9.
3. Arkin MR, Wells JA. 2004. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discovery 3: 301-17.
4. Bird RE, Hardman KD, Jacobson JW, et al. 1988. Single-chain antigen-binding proteins. Science 242: 423-6.
5. Huston JS, Levinson D, Mudgett-Hunter M, et al. 1988. Protein engineering of antibody binding sites: recovery of specific activity in an antidigoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85: 5879-83.
6. Filpula D. 2007. Antibody engineering and modification technologies. Biomol Eng 24: 201-15.
7. Lobato MN, Rabbitts TH. 2003. Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol Med 9: 390-6.
8. Miller TW, Messer A. 2005. Intrabody applications in neurological disorders: Progress and future prospects. Mol Ther 12: 394-401. (Pubitemid 41158094)
9. Worn A, Pluckthun A. 2001. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305: 989-1010.
10. Tanaka T, Lobato MN, Rabbitts TH. 2003. Single domain intracellular antibodies: A minimal fragment for direct in vivo selection of antigen-specific intrabodies. J Mol Biol 331: 1109-20.
11. Tanaka T, Rabbitts TH. 2008. Functional intracellular antibody fragments do not require invariant intra-domain disulfide bonds. J Mol Biol 376: 749-57.
12. Tanaka T, Rabbitts TH. 2008. Interfering with protein-protein interactions: potential for cancer therapy. Cell Cycle 7: 1569-74.
13. Griffin H, Elston R, Jackson D, et al. 2006. Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J Mol Biol 355: 360-78.
14. Boldicke T, Weber H, Mueller PP, et al. 2005. Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR). J Immunol Methods 300: 146-59.
15. Mhashilkar AM, Doebis C, Seifert M, et al. 2002. Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes. Gene Ther 9: 307-19.
16. Toleikis L, Broders O, Dubel S. 2004. Cloning single-chain antibody fragments (scFv) from hybridoma cells. Methods Mol Med 94: 447-58.
17. Fields S, Song. O. 1989. A novel genetic system to detect protein-protein interactions. Nature 340: 245-6. (Pubitemid 19171591)
18. Visintin M, Tse E, Axelson H, et al. 1999. Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc Natl Acad Sci USA 96: 11723-8.
19. Tse E, Lobato MN, Forster A, et al. 2002. Intracellular antibody capture technology: application to selection of single chain Fv recognising the BCR-ABL oncogenic protein. J Mol Biol 317: 85-94.
20. Visintin M, Settanni G, Maritan A, et al. 2002. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol 317: 73-83.
21. Tanaka T, Rabbitts TH. 2003. Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. EMBO J 22: 1025-35.
22. Visintin M, Meli GA, Cannistraci I, et al. 2004. Intracellular antibodies for proteomics. J Immunol Methods 290: 135-53.
23. Tanaka T, Rabbitts TH. 2010. Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture. Nat Protoc 5: 67-92.
24. Tanaka T, Williams RL, Rabbitts TH. 2007. Tumour prevention by a single antibody domain inhibiting binding of signal transduction molecules to activated RAS. EMBO J 26: 3250-9.
25. Nam CH, Lobato MN, Appert A, et al. 2008. An antibody inhibitor of the LMO2 protein complex blocks its normal and tumorigenic functions. Oncogene 27: 4962-8.
26. Wadman IA, Osada H, Grutz GG, et al. 1997. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J 16: 3145-57.
27. Appert A, Nam CH, Lobato N, et al. 2009. Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia. Cancer Res 69: 4784-90.
28. Visintin M, Melchionna T, Cannistraci I, et al. 2008. In vivo selection of intrabodies specifically targeting protein-protein interactions: a general platform for an "undruggable" class of disease targets. J Biotechnol 135: 1-15.
29. Boulianne GL, Hozumi N, Shulman MJ. 1984. Production of functional chimaeric mouse/human antibody. Nature 312: 643-6.
30. Morrison SL, Johnson MJ, Herzenberg LA, et al. 1984. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81: 6851-5.
31. Neuberger MS, Williams GT, Mitchell EB, et al. 1985. A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314: 268-70.
32. Tse E, Rabbitts TH. 2000. Intracellular antibody-caspase mediated cell killing: a novel approach for application in cancer therapy. Proc Natl Acad Sci USA 97: 12266-71.
33. Melchionna T, Cattaneo A. 2007. A protein silencing switch by ligand-induced proteasome-targeting intrabodies. J Mol Biol 374: 641-54.
34. MacCorkle RA, Freeman KW, Spencer DM. 1998. Synthetic activation of caspases: artificial death switches. Proc Natl Acad Sci USA 95: 3655-60.
35. Tanaka T, Rabbitts TH. 2009. Selection of complementary single-variable domains for building monoclonal antibodies to native proteins. Nucleic Acids Res 37: e41.
36. Weissman AM. 2001. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2: 169-78.
37. Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discovery 4: 145-60.
38. Torchilin VP. 2008. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Delivery Rev 60: 548-58.
39. Lacerda L, Raffa S, Prato M, et al. 2007. Cell-penetrating CNTs for delivery of therapeutics. Nanotoday 2: 38-43.
40. Peer D, Karp JM, Hong S, et al. 2007. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2: 751-60.
41. Pisal DS, Kosloski MP, Balu-Iyer. SV. 2010. Delivery of therapeutic proteins. J Pharm Sci 99: 2557-75.
42. Fonseca SB, Pereira MP, Kelley SO. 2009. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Delivery Rev 61: 953-64.
43. Verma IM, Weitzman MD. 2005. Gene therapy: twenty-first century medicine. Annu Rev Biochem 74: 711-38.
44. Aiuti A, Slavin S, Aker M, et al. 2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-13.
45. Thomas CE, Ehrhardt A, Kay MA. 2003. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4: 346-58. (Pubitemid 36538359)
46. Uherek C, Wels. W. 2000. DNA-carrier proteins for targeted gene delivery. Adv Drug Delivery Rev 44: 153-66.
47. Song E, Zhu P, Lee SK, et al. 2005. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709-17.
48. Kumar P., Ban HS, Kim SS, et al. 2008. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134: 577-86.
49. Rajendran L, Knolker HJ, Simons K. 2010. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discovery 9: 29-42.
50. Hayashi I, Takatori S, Urano Y, et al. 2009. Single chain variable fragment against nicastrin inhibits the gamma-secretase activity. J Biol Chem 284: 27838-47.
51. Meli G, Visintin M, Cannistraci I, et al. 2009. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. J Mol Biol 387: 584-606.
52. Paganetti P, Calanca V, Galli C, et al. 2005. Beta-site specific intra-bodies to decrease and prevent generation of Alzheimer's Abeta peptide. J Cell Biol 168: 863-8.
53. Liu R, Yuan B, Emadi S, et al. 2004. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 43: 6959-67.
54. Lecerf JM, Shirley TL, Zhu Q, et al. 2001. Human single-chain Fv intra-bodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 98: 4764-9.
55. Feldhaus MJ, Siegel RW, Opresko LK, et al. 2003. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol 21: 163-70.
56. Colby DW, Chu Y, Cassady JP, et al. 2004. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci USA 101: 17616-21.
57. Khoshnan A, Ko J, Patterson PH. 2002. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci USA 99: 1002-7.
58. Emadi S, Liu R, Yuan B, et al. 2004. Inhibiting aggregation of alphasynuclein with human single chain antibody fragments. Biochemistry 43: 2871-8.
59. Lynch SM, Zhou C, Messer A. 2008. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol 377: 136-47.
60. Marasco WA, Haseltine WA, Chen. S. 1993. Design, intracellular expression, and activity of a human anti-human immunodeficient virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 90: 7899-3.
61. Mhashilkar AM, Bagley J, Chen SY, et al. 1995. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain antibody. EMBO J 14: 1542-51.
62. + mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies. Hum Gene Ther 10: 1453-67.
63. Hartley O, Dorgham K, Perez-Bercoff D, et al. 2003. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines. J Virol 77: 6637-44.
64. Aires da Silva F, Santa-Marta M, Freitas-Vieira A, et al. 2004. Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity. J Mol Biol 340: 525-42.
65. Goncalves J, Silva F, Freitas-Vieira A, et al. 2002. Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J Biol Chem 277: 32036-45.
66. Shaheen F, Duan L, Zhu M, et al. 1996. Targeting human immunode-ficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J Virol 70: 3392-400. (Pubitemid 26157321)
67. Herschhorn A, Admon A, Hizi. A. 2003. Recombinant human antibodies against the reverse transcriptase of human immunodeficiency virus type-1. Biochim Biophys Acta 1648: 154-63.
68. Bai J, Sui J, Zhu RY, et al. 2003. Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem 278: 1433-42.
69. Duan L, Zhu M, Bagasra O, et al. 1995. Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-rev single-chain variable fragments. Hum Gene Ther 6: 1561-73. (Pubitemid 26014942)
70. Accardi L, Dona MG, Di Bonito P, et al. 2005. Intracellular anti-E7 human antibodies in single-chain format inhibit proliferation of HPV16-positive cervical carcinoma cells. Int J Cancer 116: 564-70.
71. Gennari F, Mehta S, Wang Y, et al. 2004. Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation. J Mol Biol 335: 193-207.
72. Piche A, Kasono K, Johanning F, et al. 1998. Phenotypic knock-out of the latentmembrane protein 1 Epstein-Barr virus by an intracellular single-chain antibody. Gene Ther 5: 1171-79.
73. Mukhtar MM, Li S, Li W, et al. 2009. Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription. Int J Biochem Cell Biol 41: 554-60.
74. Vascotto F, Visintin M, Cattaneo A, et al. 2005. Design and selection of an intrabody library produced de-novo for the non-structural protein NSP5 of rotavirus. J Immunol Methods 301: 31-40.
75. Corte-Real S, Collins C, Aires da Silva F, et al. 2005. Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells. Blood 106: 3797-802.
76. Serruys B, Van Houtte F, Verbrugghe P, et al. 2009. Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice. Hepatology 49: 39-49.
77. Martin F, Volpari C, Steinkuhler C, et al. 1997. Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng 10: 607-14.
78. Biocca S, Pierandrei-Amaldi P, Campioni N, et al. 1994. Intracellular immunization with cytosolic recombinant antibodies. Biotechnology 12: 396-99. (Pubitemid 124005103)
79. Caron de Fromentel C, Gruel N, Venot C, et al. 1999. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 18: 551-7.
80. Hyland S, Beerli RR, Barbas CF, et al. 2003. Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor. Oncogene 22: 1557-67.
81. Graus-Porta D, Beerli RR, Hynes NE. 1995. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 15: 1182-91.
82. Deshane J, Loechel F, Conry RM, et al. 1994. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther 1: 332-7.
83. Richardson JH, Sodroski JG, Waldmann TA, et al. 1995. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci USA 92: 3137-41.
84. Strube RW, Chen. SY. 2002. Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: Enhanced intracellular stability of novel sFv-F(c) intrabodies. J Immunol Methods 263: 149-67.
85. Popkov M, Mage RG, Alexander CB, et al. 2003. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol 325: 325-35.
86. + cells from cord blood. Stem Cells 19: 24-36.
87. Wheeler YY, Kute TE, Willingham MC, et al. 2003. Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis. FASEB J 17: 1733-5.
88. Paz K, Brennan LA, Iacolina M, et al. 2005. Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Mol Cancer Ther 4: 1801-9.
89. Liao W, Strube RW, Milne RW, et al. 2008. Cloning of apoB intrabodies: specific knockdown of apoB in HepG2 cells. Biochem Biophys Res Commun 373: 235-40.
90. Tragoolpua K, Intasai N, Kasinrerk W, et al. 2008. Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cells. BMC Biotechnol 8: 5.
91. Secco P, Ferretti M, Gioia D, et al. 2004. Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron. J Immunol Methods 285: 99-109.
92. Chartier A, Raz V, Sterrenburg E, et al. 2009. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. Hum Mol Genet 18: 1849-59.
93. Gueorguieva D, Li S, Walsh N, et al. 2006. Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis. FASEB J 20: 2636-8.
94. Zacchi P, Dreosti E, Visintin M, et al. 2008. Gephyrin selective intrabodies as a new strategy for studying inhibitory receptor clustering. J Mol Neurosci 34: 141-8.
95. Sato M, Iwaya R, Ogihara K, et al. 2005. Intrabodies against the EVH1 domain of Wiskott-Aldrich syndrome protein inhibit T cell receptor signaling in transgenic mice T cells. FEBS J 272: 6131-44.